WP
SUPN icon

WMS Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

WMS Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-73,208
Closed -$1.74M – 216
2019
Q4 		$1.74M Buy
73,208
+20
+0% +$486 0.39% 45
2019
Q3 		$2.01M Hold
73,188
– – 0.48% 41
2019
Q2 		$2.42M Hold
73,188
– – 0.6% 35
2019
Q1 		$2.56M Buy
+73,188
New +$2.72M 0.64% 32
2015
Q4 		– Sell
-65,031
Closed -$912K – 206
2015
Q3 		$912K Buy
+65,031
New +$1.21M 0.14% 80

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WMS Partners's SUPN Position: Q1 2020 in Review

WMS Partners sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 73,208 shares — an estimated $1.74M sold.

WMS Partners first reported a position in SUPN in Q3 2015 and held it in 5 quarters. The position peaked at $2.56M in Q1 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • WMS Partners reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • WMS Partners sold 73,208 Supernus Pharmaceuticals shares in Q1 2020, an estimated $1.74M.
  • WMS Partners first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • WMS Partners's Supernus Pharmaceuticals position peaked at $2.56M in Q1 2019.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on WMS Partners's 13F filing for Q1 2020, filed 13 May 2020.